BR9406941A - Formulação oral com revestimento entèrico processo para a preparação da formulação processo para a inibição da secreção de acido gástrico em mamiferos e no homem e processo para o tratamento de doencas relacionados ao ácidos gástrico em mamiferos e no homem - Google Patents

Formulação oral com revestimento entèrico processo para a preparação da formulação processo para a inibição da secreção de acido gástrico em mamiferos e no homem e processo para o tratamento de doencas relacionados ao ácidos gástrico em mamiferos e no homem

Info

Publication number: BR9406941A
Authority: BR; Brazil
Prior art keywords: mammals; man; gastric acid; formulation; inhibition
Prior art date: 1993-07-09

Application number

BR9406941A

Other languages

English (en)

Inventor

Inge Siv Bengtsson

Kurt Ingmar Lovgren

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-07-09

Filing date

1994-07-08

Publication date

1996-09-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9406941(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-07-08 Application filed by Astra Ab filed Critical Astra Ab

1996-09-10 Publication of BR9406941A publication Critical patent/BR9406941A/pt

Links

238000009472 formulation Methods 0.000 title abstract 4
238000000034 method Methods 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
241000124008 Mammalia Species 0.000 title 2
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000002702 enteric coating Substances 0.000 title 1
238000009505 enteric coating Methods 0.000 title 1
210000004211 gastric acid Anatomy 0.000 title 1
230000027119 gastric acid secretion Effects 0.000 title 1
230000005764 inhibitory process Effects 0.000 title 1
238000002360 preparation method Methods 0.000 title 1
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
159000000003 magnesium salts Chemical class 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
229960000381 omeprazole Drugs 0.000 abstract 1
239000008203 oral pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BR9406941A 1993-07-09 1994-07-08 Formulação oral com revestimento entèrico processo para a preparação da formulação processo para a inibição da secreção de acido gástrico em mamiferos e no homem e processo para o tratamento de doencas relacionados ao ácidos gástrico em mamiferos e no homem BR9406941A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE19939302395A SE9302395D0 (sv)	1993-07-09	1993-07-09	New pharmaceutical formulation
PCT/SE1994/000681 WO1995001783A1 (en)	1993-07-09	1994-07-08	New pharmaceutical formulation

Publications (1)

Publication Number	Publication Date
BR9406941A true BR9406941A (pt)	1996-09-10

Family

ID=20390587

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9406941A BR9406941A (pt)	1993-07-09	1994-07-08	Formulação oral com revestimento entèrico processo para a preparação da formulação processo para a inibição da secreção de acido gástrico em mamiferos e no homem e processo para o tratamento de doencas relacionados ao ácidos gástrico em mamiferos e no homem

Country Status (40)

Country	Link
US (1)	US5690960A (pt)
EP (1)	EP0706378B1 (pt)
JP (1)	JP3665334B2 (pt)
KR (1)	KR100350203B1 (pt)
CN (1)	CN1126946A (pt)
AT (1)	ATE231719T1 (pt)
AU (1)	AU681686B2 (pt)
BR (1)	BR9406941A (pt)
CA (1)	CA2166483C (pt)
CZ (1)	CZ290323B6 (pt)
DE (1)	DE69432076T2 (pt)
DK (1)	DK0706378T3 (pt)
DZ (1)	DZ1794A1 (pt)
EE (1)	EE03148B1 (pt)
EG (1)	EG22373A (pt)
ES (1)	ES2191682T3 (pt)
FI (1)	FI114008B (pt)
HK (1)	HK1008299A1 (pt)
HR (1)	HRP940386B1 (pt)
HU (1)	HU226779B1 (pt)
IL (1)	IL110189A0 (pt)
IS (1)	IS2034B (pt)
LV (1)	LV13140B (pt)
MA (1)	MA23258A1 (pt)
MX (1)	MX9405219A (pt)
MY (1)	MY128809A (pt)
NO (1)	NO315146B1 (pt)
NZ (1)	NZ268694A (pt)
PL (1)	PL175210B1 (pt)
RU (1)	RU2138254C9 (pt)
SA (1)	SA94150057B1 (pt)
SE (1)	SE9302395D0 (pt)
SG (1)	SG52365A1 (pt)
SI (1)	SI0706378T1 (pt)
SK (1)	SK281105B6 (pt)
TN (1)	TNSN94078A1 (pt)
UA (1)	UA43342C2 (pt)
WO (1)	WO1995001783A1 (pt)
YU (1)	YU49199B (pt)
ZA (1)	ZA944934B (pt)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9301830D0 (sv) *	1993-05-28	1993-05-28	Ab Astra	New compounds
US6875872B1 (en) *	1993-05-28	2005-04-05	Astrazeneca	Compounds
SE9302395D0 (sv) *	1993-07-09	1993-07-09	Ab Astra	New pharmaceutical formulation
SE9402431D0 (sv) *	1994-07-08	1994-07-08	Astra Ab	New tablet formulation
DK1078628T3 (da) *	1994-07-08	2009-02-23	Astrazeneca Ab	Tabletteret flerenhedsdoseringsform
WO1996001622A1 (en) *	1994-07-08	1996-01-25	Astra Aktiebolag	New oral pharmaceutical formulation containing magnesium salt of omeprazole
SE9500478D0 (sv) *	1995-02-09	1995-02-09	Astra Ab	New pharmaceutical formulation and process
CR5278A (es) *	1995-03-24	1996-07-04	Lilly Co Eli	Formulacion oral de 2-metil-tieno-benzodiacepina
US5945124A (en) *	1995-07-05	1999-08-31	Byk Gulden Chemische Fabrik Gmbh	Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6489346B1 (en)	1996-01-04	2002-12-03	The Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
US5840737A (en)	1996-01-04	1998-11-24	The Curators Of The University Of Missouri	Omeprazole solution and method for using same
US6645988B2 (en)	1996-01-04	2003-11-11	Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en)	1996-01-04	2004-03-02	The Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and methods of using same
SE512835C2 (sv) *	1996-01-08	2000-05-22	Astrazeneca Ab	Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE508669C2 (sv) *	1996-04-26	1998-10-26	Astra Ab	Nytt förfarande
DE19626045C2 (de) *	1996-06-28	1998-12-03	Klinge Co Chem Pharm Fab	Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6623759B2 (en)	1996-06-28	2003-09-23	Astrazeneca Ab	Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
HUP9904065A3 (en) *	1996-09-24	2001-10-29	Lilly Co Eli	Coated particle formulations containing olanzapine
TW385306B (en) *	1996-11-14	2000-03-21	Takeda Chemical Industries Ltd	Method for producing crystals of benzimidazole derivatives
JP2001524131A (ja) *	1997-05-09	2001-11-27	セイジ、ファーマスーティカルズ、インク	安定な経口医薬品剤形
SE9702000D0 (sv) *	1997-05-28	1997-05-28	Astra Ab	New pharmaceutical formulation
US6747155B2 (en)	1997-05-30	2004-06-08	Astrazeneca Ab	Process
SE510650C2 (sv)	1997-05-30	1999-06-14	Astra Ab	Ny förening
SI9700186B (sl) *	1997-07-14	2006-10-31	Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D.	Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US20050244497A1 (en) *	1997-11-05	2005-11-03	Wockhardt Limited	Delayed delivery system for acid-sensitive drugs
US6096340A (en) *	1997-11-14	2000-08-01	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
US6174548B1 (en)	1998-08-28	2001-01-16	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
AU1671799A (en) *	1997-11-28	1999-06-16	Byk Gulden Lomberg Chemische Fabrik Gmbh	Medicament preparation in the form of a tablet or pellet for acid-labile active substances
SE9704870D0 (sv)	1997-12-22	1997-12-22	Astra Ab	New pharmaceutical formulation I
US20020039597A1 (en) *	1998-04-20	2002-04-04	Koji Ukai	Stabilized compositions containing benzimidazole-type compounds
UA73092C2 (uk) *	1998-07-17	2005-06-15	Брістол-Майерс Сквібб Компані	Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US7094426B2 (en) *	1998-08-27	2006-08-22	Sage Pharmaceuticals, Inc.	Stable oral pharmaceutical dosage forms
US6733778B1 (en)	1999-08-27	2004-05-11	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
SE9803772D0 (sv) *	1998-11-05	1998-11-05	Astra Ab	Pharmaceutical formulation
IL142703A (en) *	1998-11-10	2006-04-10	Astrazeneca Ab	Crystalline form of omeprazole
UA72748C2 (en) *	1998-11-10	2005-04-15	Astrazeneca Ab	A novel crystalline form of omeprazole
EP1131316B1 (en)	1998-11-18	2004-07-21	AstraZeneca AB	Improved chemical process and pharmaceutical formulation
US6365128B1 (en) *	1998-12-18	2002-04-02	Medical Defence Technologies, Llc	Monitoring gastrointestinal function to guide care of high risk patients
IL145688A0 (en) *	1999-03-29	2002-06-30	American Home Prod	Coating system
SE9902386D0 (sv) *	1999-06-22	1999-06-22	Astra Ab	New formulation
IL130602A0 (en) *	1999-06-22	2000-06-01	Dexcel Ltd	Stable benzimidazole formulation
US6245913B1 (en)	1999-06-30	2001-06-12	Wockhardt Europe Limited	Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6500459B1 (en) *	1999-07-21	2002-12-31	Harinderpal Chhabra	Controlled onset and sustained release dosage forms and the preparation thereof
US6316020B1 (en) *	1999-08-26	2001-11-13	Robert R. Whittle	Pharmaceutical formulations
RU2259828C2 (ru)	1999-10-20	2005-09-10	Эйсай Ко., Лтд.	Способы стабилизации соединений на основе бензимидазола
CA2409258A1 (en) *	2000-05-15	2001-11-22	Ranbaxy Laboratories Limited	Novel amorphous form of omeprazole salts
ES2191521B1 (es) *	2000-11-22	2005-02-16	Laboratorios Belmac, S.A.	Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
US20030070584A1 (en)	2001-05-15	2003-04-17	Cynthia Gulian	Dip coating compositions containing cellulose ethers
US8206741B2 (en)	2001-06-01	2012-06-26	Pozen Inc.	Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8309118B2 (en)	2001-09-28	2012-11-13	Mcneil-Ppc, Inc.	Film forming compositions containing sucralose
PT2258351E (pt) *	2001-10-17	2013-07-29	Takeda Pharmaceutical	Grânulos contendo lansoprazole em grande quantidade
US20040006111A1 (en) *	2002-01-25	2004-01-08	Kenneth Widder	Transmucosal delivery of proton pump inhibitors
WO2003075825A2 (en) *	2002-03-08	2003-09-18	Modi, Rajiv, Indravadan	The method of treating tuberculosis
AU2003244647B2 (en) *	2002-08-02	2008-04-17	Ratiopharm Gmbh	Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
US7429619B2 (en)	2002-08-02	2008-09-30	Mcneil Consumer Healthcare	Polyacrylic film forming compositions
MY148805A (en)	2002-10-16	2013-05-31	Takeda Pharmaceutical	Controlled release preparation
AU2003900096A0 (en) *	2003-01-10	2003-02-20	Nature Vet	Orally deliverable pharmaceutical composition protein pump inhibitors
ITMI20030616A1 (it) *	2003-03-28	2004-09-29	Acme Drugs S R L	Metodo per la preparazione di farmaci, alimenti, integratori alimentari, gastroprotetti e/o a rilascio controllato, prodotti dietetici, premiscele per mangim,i additivi per l'alimentazione zootecnica contenenti principi attivi sensibili all'ambiente
US8993599B2 (en)	2003-07-18	2015-03-31	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045068A1 (es) *	2003-07-23	2005-10-12	Univ Missouri	Formulacion de liberacion inmediata de composiciones farmaceuticas
MXPA06002443A (es) *	2003-09-03	2006-08-31	Agi Therapeutics Ltd	Formulaciones inhibidoras de la bomba de protones y metodos para preparar y utilizar tales formulaciones.
US20050214388A1 (en) *	2004-02-18	2005-09-29	Gorham Thomas R	Multivitamin formulations containing controlled-release magnesium
WO2005082888A1 (en) *	2004-03-01	2005-09-09	Milen Merkez Ilac Endustrisi A.S.	Process for the preparation of magnesium salt of omeprazole
US8815916B2 (en)	2004-05-25	2014-08-26	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en)	2004-05-25	2014-12-09	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2570916C (en)	2004-06-16	2013-06-11	Tap Pharmaceutical Products, Inc.	Pulsed release dosage form of a ppi
US20060024362A1 (en)	2004-07-29	2006-02-02	Pawan Seth	Composition comprising a benzimidazole and process for its manufacture
CN101111233A (zh)	2004-12-23	2008-01-23	兰贝克赛实验室有限公司	稳定的口服苯并咪唑组合物及其制备方法
US20080279951A1 (en) *	2005-02-02	2008-11-13	Rajesh Gandhi	Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
EP2275088B2 (en) *	2005-02-25	2018-09-26	Takeda Pharmaceutical Company Limited	Method for producing granules
JP2009511481A (ja) *	2005-10-06	2009-03-19	オースペックス・ファーマシューティカルズ・インコーポレイテッド	増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤
US20100297226A1 (en) *	2006-06-01	2010-11-25	Dexcel Pharma Technologies Ltd.	Multiple unit pharmaceutical formulation
WO2008014175A2 (en) *	2006-07-28	2008-01-31	Dr. Reddy's Laboratories Ltd.	Granular pharmaceutical compositions
GB2459393B (en)	2006-10-05	2010-09-08	Santarus Inc	Novel capsule formulation for the proton pump inhibitor omeprazole
WO2008057802A2 (en)	2006-10-27	2008-05-15	The Curators Of The University Of Missouri	Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US20080194307A1 (en) *	2007-02-13	2008-08-14	Jeff Sanger	Sports-based game of chance
WO2009113090A2 (en) *	2008-01-17	2009-09-17	Alkem Laboratories Ltd.	Process for preparing an oral formulation of an acid-sensitive benzimidazole drug
CN101980700A (zh)	2008-02-20	2011-02-23	密苏里大学董事会	包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法
US8911787B2 (en)	2008-02-26	2014-12-16	Ranbaxy Laboratories Limited	Stable oral benzimidazole compositions and process of preparation thereof
ES2552723T3 (es) *	2008-05-06	2015-12-01	Dexcel Pharma Technologies Ltd.	Formulación de bencimidazol estable
WO2009137648A1 (en) *	2008-05-09	2009-11-12	Aptapharma, Inc.	Multilayer proton pump inhibitor tablets
CA2736547C (en)	2008-09-09	2016-11-01	Pozen Inc.	Method for delivering a pharmaceutical composition to patient in need thereof
RU2743637C2 (ru) *	2009-01-09	2021-02-20	Фвп Ип Апс	Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице
CN102481293A (zh)	2009-06-25	2012-05-30	阿斯利康(瑞典)有限公司	治疗具有发展nsaid-相关的溃疡的风险的患者的方法
EP2345408A3 (en)	2010-01-08	2012-02-29	Dr. Reddy's Laboratories Ltd.	Acid labile drug formulations
EP3711658A1 (en)	2011-06-14	2020-09-23	Gravitas Medical Inc.	Apparatus for guiding medical care based on detected gastric function
EA028049B1 (ru)	2011-12-28	2017-10-31	Поузен Инк.	Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
CN103127026B (zh) *	2013-02-05	2017-02-15	悦康药业集团有限公司	一种奥美拉唑肠溶胶囊及其制备方法
CN103735526A (zh) *	2013-08-08	2014-04-23	上海海虹实业(集团)巢湖今辰药业有限公司	奥美拉唑镁肠溶片及其制作方法
CN103467453A (zh) *	2013-09-13	2013-12-25	上海海虹实业(集团)巢湖今辰药业有限公司	一种奥美拉唑镁原料药制备方法
WO2016174664A1 (en)	2015-04-29	2016-11-03	Dexcel Pharma Technologies Ltd.	Orally disintegrating compositions
US10736855B2 (en)	2016-02-25	2020-08-11	Dexcel Pharma Technologies Ltd.	Compositions comprising proton pump inhibitors
US10076494B2 (en)	2016-06-16	2018-09-18	Dexcel Pharma Technologies Ltd.	Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs)	2017-06-02	2018-12-12	Zentiva, K.S.	Dávkovací jednotka s PPI (inhibitory protonové pumpy)
WO2021153525A1 (ja)	2020-01-27	2021-08-05	東和薬品株式会社	エソメプラゾール経口製剤およびその製造方法
US11426353B2 (en) *	2020-06-24	2022-08-30	13400719 Canada Inc.	Composite coating for an active agent
CN113350313B (zh) *	2021-06-23	2023-08-11	福建金山生物制药股份有限公司	一种艾司奥美拉唑镁延释制剂及其制备方法
WO2024075017A1 (en)	2022-10-04	2024-04-11	Zabirnyk Arsenii	Inhibition of aortic valve calcification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7804231L (sv) *	1978-04-14	1979-10-15	Haessle Ab	Magsyrasekretionsmedel
SE8301182D0 (sv) *	1983-03-04	1983-03-04	Haessle Ab	Novel compounds
GB2189698A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated omeprazole tablets
JPH0768125B2 (ja) *	1988-05-18	1995-07-26	エーザイ株式会社	酸不安定化合物の内服用製剤
SE9302396D0 (sv) *	1993-07-09	1993-07-09	Ab Astra	A novel compound form
SE9302395D0 (sv) *	1993-07-09	1993-07-09	Ab Astra	New pharmaceutical formulation

1993
- 1993-07-09 SE SE19939302395A patent/SE9302395D0/xx unknown
1994
- 1994-07-01 HR HR940386A patent/HRP940386B1/xx not_active IP Right Cessation
- 1994-07-01 IL IL11018994A patent/IL110189A0/xx not_active IP Right Cessation
- 1994-07-03 DZ DZ940072A patent/DZ1794A1/fr active
- 1994-07-04 SA SA94150057A patent/SA94150057B1/ar unknown
- 1994-07-06 IS IS4187A patent/IS2034B/is unknown
- 1994-07-07 ZA ZA944934A patent/ZA944934B/xx unknown
- 1994-07-07 MA MA23568A patent/MA23258A1/fr unknown
- 1994-07-07 EG EG40894A patent/EG22373A/xx active
- 1994-07-07 MY MYPI94001776A patent/MY128809A/en unknown
- 1994-07-08 CA CA002166483A patent/CA2166483C/en not_active Expired - Lifetime
- 1994-07-08 PL PL94312441A patent/PL175210B1/pl unknown
- 1994-07-08 RU RU96102154/14A patent/RU2138254C9/ru active
- 1994-07-08 WO PCT/SE1994/000681 patent/WO1995001783A1/en active IP Right Grant
- 1994-07-08 SK SK21-96A patent/SK281105B6/sk not_active IP Right Cessation
- 1994-07-08 DE DE69432076T patent/DE69432076T2/de not_active Expired - Lifetime
- 1994-07-08 JP JP50400695A patent/JP3665334B2/ja not_active Expired - Lifetime
- 1994-07-08 SI SI9430438T patent/SI0706378T1/xx unknown
- 1994-07-08 BR BR9406941A patent/BR9406941A/pt not_active Application Discontinuation
- 1994-07-08 NZ NZ268694A patent/NZ268694A/en not_active IP Right Cessation
- 1994-07-08 EP EP94921155A patent/EP0706378B1/en not_active Expired - Lifetime
- 1994-07-08 KR KR1019960700052A patent/KR100350203B1/ko not_active IP Right Cessation
- 1994-07-08 HU HU9503874A patent/HU226779B1/hu unknown
- 1994-07-08 AT AT94921155T patent/ATE231719T1/de active
- 1994-07-08 AU AU71982/94A patent/AU681686B2/en not_active Expired
- 1994-07-08 US US08/313,036 patent/US5690960A/en not_active Expired - Lifetime
- 1994-07-08 CN CN94192734A patent/CN1126946A/zh active Pending
- 1994-07-08 UA UA96010058A patent/UA43342C2/uk unknown
- 1994-07-08 MX MX9405219A patent/MX9405219A/es unknown
- 1994-07-08 TN TNTNSN94078A patent/TNSN94078A1/fr unknown
- 1994-07-08 DK DK94921155T patent/DK0706378T3/da active
- 1994-07-08 CZ CZ199670A patent/CZ290323B6/cs not_active IP Right Cessation
- 1994-07-08 ES ES94921155T patent/ES2191682T3/es not_active Expired - Lifetime
- 1994-07-08 SG SG1996003536A patent/SG52365A1/en unknown
- 1994-07-08 YU YU43794A patent/YU49199B/sh unknown
- 1994-11-17 EE EE9400419A patent/EE03148B1/xx unknown
1996
- 1996-01-05 NO NO19960067A patent/NO315146B1/no not_active IP Right Cessation
- 1996-01-09 FI FI960102A patent/FI114008B/fi not_active IP Right Cessation
1998
- 1998-07-17 HK HK98109229A patent/HK1008299A1/xx not_active IP Right Cessation
2004
- 2004-01-22 LV LVP-04-07A patent/LV13140B/en unknown

Also Published As

Publication number	Publication date
HK1008299A1 (en)	1999-05-07
CZ290323B6 (cs)	2002-07-17
CN1126946A (zh)	1996-07-17
IS2034B (is)	2005-08-15
HUT75306A (en)	1997-05-28
ATE231719T1 (de)	2003-02-15
CA2166483C (en)	1997-09-16
US5690960A (en)	1997-11-25
EG22373A (en)	2002-12-31
PL312441A1 (en)	1996-04-29
EE03148B1 (et)	1999-02-15
HU9503874D0 (en)	1996-02-28
CZ7096A3 (en)	1996-06-12
MX9405219A (es)	1995-01-31
AU681686B2 (en)	1997-09-04
IL110189A0 (en)	1994-10-21
EP0706378A1 (en)	1996-04-17
KR100350203B1 (ko)	2002-12-28
WO1995001783A1 (en)	1995-01-19
EP0706378B1 (en)	2003-01-29
NO315146B1 (no)	2003-07-21
UA43342C2 (uk)	2001-12-17
SK2196A3 (en)	1997-04-09
MA23258A1 (fr)	1995-04-01
LV13140B (en)	2004-08-20
FI960102A (fi)	1996-01-09
SG52365A1 (en)	1998-09-28
RU2138254C1 (ru)	1999-09-27
NO960067L (no)	1996-01-05
PL175210B1 (pl)	1998-11-30
RU2138254C9 (ru)	2009-09-27
ES2191682T3 (es)	2003-09-16
SA94150057B1 (ar)	2006-10-03
SE9302395D0 (sv)	1993-07-09
YU49199B (sh)	2004-09-03
TNSN94078A1 (fr)	1995-04-25
HRP940386A2 (en)	1997-02-28
DE69432076T2 (de)	2003-10-16
HRP940386B1 (en)	2003-10-31
CA2166483A1 (en)	1995-01-19
FI114008B (fi)	2004-07-30
ZA944934B (en)	1995-02-20
AU7198294A (en)	1995-02-06
IS4187A (is)	1995-01-10
SI0706378T1 (en)	2003-06-30
DK0706378T3 (da)	2003-05-05
YU43794A (sh)	1997-07-31
HU226779B1 (en)	2009-10-28
DZ1794A1 (fr)	2002-02-17
SK281105B6 (sk)	2000-12-11
NZ268694A (en)	1997-05-26
MY128809A (en)	2007-02-28
JPH08512316A (ja)	1996-12-24
NO960067D0 (no)	1996-01-05
FI960102A0 (fi)	1996-01-09
JP3665334B2 (ja)	2005-06-29
DE69432076D1 (de)	2003-03-06

Legal Events

Date	Code	Title	Description
1999-09-14	EG	Technical examination (opinion): publication of technical examination (opinion)
2000-03-21	FC	Decision: refusal

Publication	Publication Date	Title
BR9406941A (pt)	1996-09-10	Formulação oral com revestimento entèrico processo para a preparação da formulação processo para a inibição da secreção de acido gástrico em mamiferos e no homem e processo para o tratamento de doencas relacionados ao ácidos gástrico em mamiferos e no homem
ATE204178T1 (de)	2001-09-15	Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
BR9406940A (pt)	1996-09-10	Magnésio-omeprazol processo para a preparação de magnésio-omeprazol composição farmacêutica formulação farmacêutica para a administração oral forumulação de tablete uso do magnesio-omeprazol processo para a inibição da secreção de ácido gástrico em mamiferos e no homem e processo para o tratamento das doenças relacionadas com o ácido gastrico em mamiferos e no homem
NO304889B1 (no)	1999-03-01	Imidazopyridiner og deres anvendelse ved fremstilling av legemidler til behandling av mave-tarm-sykdommer
GR861803B (en)	1986-11-10	Novel carbonic acid derivatives method for their preparation their use and medicine containing them
ATE217197T1 (de)	2002-05-15	Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
IL125819A0 (en)	1999-04-11	Morphine and diamorphine salts of anionic non-narcotic analgesics of the substituted carboxylic acid type processes for the preparation thereof and pharmaceutical compositions containing the same
DE3878111D1 (de)	1993-03-18	Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung.
ATE143947T1 (de)	1996-10-15	N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
FI925944A (fi)	1992-12-30	Arylalkylestrar av 4,5-dihydroxi-9,10-dihydro-9,10-dioxo-2-antracenkarboxylsyra med terapeutisk effekt
IL88726A0 (en)	1989-07-31	Dihydrothienobenzodiazepinone derivatives,pharmaceutical compositions containing the same and processes for the preparation thereof
PT98764A (pt)	1993-09-30	Processo para a preparacao de composicoes contendo factor de desenvolvimento de insulina 1 completo para o tratamento terapeutico ou profilactico de estado catabolicos
UA15281A (uk)	1997-06-30	Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця